Alka seltzer recalled by Bayer

Source: Sina pharmaceutical 2018-03-19 at present, Bayer's sales performance in its important consumer health business is worrying This week, the company announced another recall of alka seltzer due to packaging problems Alka seltzer Yangwei effervescent tablet can quickly relieve dyspepsia, heartburn, flatulence, stomach acid, headache and body pain caused by stomach discomfort, and it is also very effective for stomach discomfort caused by drinking When the stomach feels uncomfortable, dissolve 2 tablets in 110ml white boiled water each time, and the stomach discomfort can be relieved quickly It can be taken every 4 hours as required, but not more than 8 tablets a day This is the second recall of the drug in less than a year, which is mainly the alka seltzer sold in Wal Mart, CVS pharmacy, Walgreens and Kroger stores after February 9 The wrong drug ingredients may have been marked on the packaging of these batches of drugs Bayer pointed out that this error may cause "serious health consequences", but stressed that there are no actual cases reported at present In response, a Bayer spokesman declined to disclose the total number of recalled drugs affected The white Bayer logo on the lower left corner of the drug package is not included in the recall scope, while the orange and green Bayer logo is the scope of the recall Bayer's consumer health sales reached 5.86 billion euros (45.54 billion yuan) in 2017, down 1.7% from the same period last year In a statement, Werner Baumann, Bayer's chief executive, said the results were partly due to the continued weakness in US business development, said Jeremy, a Bernstein analyst In addition to problems in the U.S business, Chinese authorities turned two Bayer over-the-counter skin care brands into prescription drugs, which directly reduced sales by 70 million euros (about 544 million yuan), redenius said For 2018, Bayer directly lowered its sales, and the pharmaceutical company predicted that this year's sales might reach 5.5 billion euros, which marks a further decline in business performance compared with 2017 Obviously, Bayer's own expectation is far from the 6 billion euros previously predicted by Wall Street Marijn Dekkers, a former CEO of Bayer, expects Bayer to be at the top of the over-the-counter drug market chain and acquire Merck's consumer health assets for $14.2 billion in 2014 But in terms of the latest development, consumers' health care and generic drugs lead to low profit margin, and Bayer is facing greater pricing pressure in the U.S market To help get the business back on track, Bayer introduced Heiko Schipper, former executive of Nestle, as a member of the management committee in November last year, and the appointment will take effect on March 1, 2018 He will replace Erica Mann as head of Bayer's health consumer products division, headquartered in Basel, Switzerland Heiko is the head of Nestle Nutrition The division is the global leader in infant nutrition with sales of 8.8 billion euros By contrast, GlaxoSmithKline, another top over-the-counter drug maker, saw sales grow by 2% in 2017 to 7.8 billion pounds (68.8 billion yuan) At the same time, Bayer is in the process of reaching a final agreement with Monsanto, a global agricultural and chemical giant, a deal that has raised concerns among some industry observers that Bayer despises the pharmaceutical business Bayer believes that farmers are expected to obtain significant benefits in a long-term way, that is, "from improving procurement and convenience to increasing production, better environmental protection and sustainable development" Bloomberg reported on Thursday that although the deal was announced in 2016, it has not yet won the scrutiny of U.S antitrust regulators.